Trials / Completed
CompletedNCT00945334
Neomycin and Rifaximin Plus Neomycin in Treating Methane Positive Constipation Predominant Irritable Bowel Syndrome
Double-blind, Placebo Controlled Trial Comparing Neomycin to Rifaximin Plus Neomycin in the Treatment of Methane Positive Subjects With Constipation-predominant Irritable Bowel Syndrome
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 37 (actual)
- Sponsor
- Mark Pimentel, MD · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
In this study the investigators aim to compare the efficacy of neomycin to a combination of rifaximin and neomycin in the treatment of C-IBS subjects with methane on their breath test. This study will be conducted in collaboration with Dr. John DiBaise at the Mayo Clinic in Scottsdale, AZ and Dr. Satish Rao in Georgia Regents University in Augusta, GA.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Neomycin | 500 mg po bid for 14 days |
| DRUG | Placebo | placebo for 14 days tid |
| DRUG | Rifaximin | 550 mg po tid |
Timeline
- Start date
- 2009-08-01
- Primary completion
- 2013-06-01
- Completion
- 2013-06-01
- First posted
- 2009-07-24
- Last updated
- 2015-08-10
- Results posted
- 2015-08-10
Locations
2 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00945334. Inclusion in this directory is not an endorsement.